CSIMarket
 


Merck and Co Inc   (MRK)
Other Ticker:  
 

Merck And Co Inc 's

Competitiveness


 

MRK Sales vs. its Competitors Q4 2020



Comparing the results to its competitors, Merck And Co Inc reported Total Revenue increase in the 4 quarter 2020 by 5.45 % year on year.
The revenue growth was below Merck And Co Inc 's competitors average revenue growth of 9.03 %, recorded in the same quarter.

List of MRK Competitors





Revenue Growth Comparisons




Net Income Comparison


Merck and Co Inc recorded net loss and most of company's competitors saw decline in earnings by -88.86 %

<<  More on MRK Income Comparisons


Merck And Co Inc 's Comment on Competitors and Industry Peers


The markets in which the Company conducts its business and the pharmaceutical industry are highly competitive and highly regulated. The Company’s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer and animal health care manufacturers. The Company’s operations may be adversely affected by generic and biosimilar competition as the Company’s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors’ branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent positions are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures have intensified as pressures in the industry have grown. The effect on operations of competitive factors and patent disputes cannot be predicted.

Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well positioned to compete in the search for technological innovations. Additional resources required to meet market challenges include quality control, flexibility to meet customer specifications, an efficient distribution system and a strong technical information service. The Company is active in acquiring and marketing products through external alliances, such as joint ventures and licenses, and has been refining its sales and marketing efforts to further address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales for the Company’s products in that therapeutic category.
The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company’s products, effective promotional efforts and the frequent introduction of generic products by competitors.

The Company’s consumer care operations face competition from other consumer health care businesses as well as retailers who carry their own private label brands. The Company’s competitive position is affected by several factors, including regulatory and legislative issues, scientific and technological advances, the quality and price of the Company’s products, promotional efforts and the growth of lower cost private label brands.

Health Care Environment
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. In the United States, federal and state governments for many years also have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for outpatient medicines purchased by certain Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.

Company’s. Guidelines for examining reference pricing are usually set in local markets and can be changed pursuant to local regulations.
In addition, in Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order repricings for classes of drugs if it determines that it is appropriate under applicable rules.

Certain markets outside of the United States have also implemented cost management strategies, such as health technology assessments, which require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.
The Company’s focus on and share of revenue from emerging markets has increased. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and related measures, such as compulsory licenses, that aim to put pressure on the price of pharmaceuticals and constrain market access. The Company anticipates that pricing pressures and market access challenges will continue in 2014 to varying degrees in the emerging markets.

Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company’s efforts to continue to grow in these markets, including potential political instability, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, and other developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company’s risk exposure.

In addressing cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens’ access to appropriate health care, including medicines.

Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company’s business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well positioned to respond to the evolving health care environment and market forces.





  

All Other Segment Market Share Q4 2020

All Other segment, revenue fell by -35.96 % and company lost market share, to approximate 35.26 %.





<<  More on MRK Market Share.
 

  

Cancidas Segment Market Share Q4 2020

Cancidas segment, revenue fell by -24.04 % and company lost market share, to approximate 22.86 %.





<<  More on MRK Market Share.
 

  

CozaarHyzaar Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 2.54 %.



<<  More on MRK Market Share.
 

  

Isentress Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 20.5 %.



<<  More on MRK Market Share.
 

  

Januvia Segment Market Share Q4 2020

Due to outstanding performance in Januvia segment, revenue grew by 2882.35 % Merck and Co Inc improved its market share, to approximate 11.45 %.





<<  More on MRK Market Share.
 

  

Other Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 56.28 %.



<<  More on MRK Market Share.
 

  

Proscar Segment Market Share Q4 2020

Proscar segment, revenue fell by -37.88 % and company lost market share, to approximate 16.94 %.





<<  More on MRK Market Share.
 

  

Remicade Segment Market Share Q4 2020

Remicade segment, revenue fell by -26.82 % and company lost market share, to approximate 3.86 %.





<<  More on MRK Market Share.
 

  

Singulair Segment Market Share Q4 2020

Singulair segment, revenue fell by -7.8 % and company lost market share, to approximate 1.71 %.





<<  More on MRK Market Share.
 

  

Vaccines Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 57.43 %.



<<  More on MRK Market Share.
 

  

Zetia Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 7.99 %.



<<  More on MRK Market Share.
 

  

Zocor Segment Market Share Q4 2020

despite revenue deterioration, Merck And Co Inc inceased its market share in this segment.

company inceased its market share in this segment to approximate 0.69 %.



<<  More on MRK Market Share.
 

*Market share is not actual measurement, only performance comparison of companies which report and operate within the same segment.


MRK's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Merck and Co Inc 47,994 184,398 7,082 70,000
Abbvie inc 45,804 192,531 4,622 26,000
Abbott Laboratories 34,608 214,470 4,495 77,000
Actavis Plc 10,573 4,714 -751 19,200
Amgen Inc 32,341 131,578 7,264 17,900
Bristol Myers Squibb Co 42,518 144,141 -8,995 25,000
Cephalon, Inc. 0 0 0 0
Johnson and Johnson 82,584 424,197 14,714 126,500
Eli Lilly And Company 24,540 187,683 6,194 39,135
Mylan N v 16,861 8,208 266 25,000
Pfizer Inc 41,908 189,654 9,652 78,300
SCHERING-PLOUGH CORPORATION 0 0 0 0
Watson Pharmaceuticals Inc 0 0 0 0
MEDIMMUNE, INC. 0 0 0 0
Procter and Gamble Co 72,897 323,080 13,373 110,000
Wyeth 0 0 0 0
Celgene Corp 16,982 78,961 1,834 6,012
Gilead Sciences Inc 24,689 77,732 89 7,000
Baxter International Inc 11,673 0 1,110 0
Hospira Inc 6,921 0 -8 0
Patterson Companies Inc 5,542 2,995 -508 7,000
Petvivo Holdings Inc 0 68 -4 4
Allergan plc 16,096 64,063 -2,479 10,500
Biogen Inc 13,445 42,024 4,061 7,550
Covidien Plc 10,880 0 1,605 39,500
SUBTOTAL 558,856 2,270,498 63,616 691,601


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NLSN's Profile

Stock Price

NLSN's Financials

Business Description

Fundamentals

Charts & Quotes

NLSN's News

Suppliers

NLSN's Competitors

Customers & Markets

Economic Indicators

NLSN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071